Repligen says HSR waiting period expires for BioLife Solutions deal

• Repligen has agreed to acquire BioLife Solutions for USD 11.25 in cash and 0.14 Repligen shares per BioLife share.
• The required antitrust waiting period expired on Sept. 3, 2026, clearing a key closing condition.
• Completion still hinges on remaining customary conditions, including BioLife shareholder adoption at a special meeting set for Oct. 5, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Repligen Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-385380), on September 08, 2026, and is solely responsible for the information contained therein.